tbuckley/cabot-search huggingface dataset:
The impact of living with transfeminine vocal gender dysphoria: Health utility outcomes assessment
Authors: Brian Nuyen, Cherian Kandathil, Daniella McDonald, James Thomas, Sam P. Most
Journal: International Journal of Transgender Health (2021)

Background: The voice signals a tremendous amount of gender cues. Transfeminine individuals report debilitating quality-of-life deficits as a result of their vocal gender dysphoria.Aims: We aimed to quantify the potential impact of this dysphoria experienced with quality-adjusted life years (QALYs), as well as associated treatments, through validated health utility measures. Methods: Peri-operative phonometric audio recordings of a consented transfeminine patient volunteer with a history of vocal gender dysphoria aided in the description of two transfeminine health states, pre- and post-vocal feminization gender dysphoria; monocular and binocular blindness were health state controls. Survey responses from general population adults rate these four health states via visual analogue scale (VAS), standard gamble (SG), and time tradeoff (TTO). Results: Survey respondents totaled 206 with a mean age of 35.8 years. Through VAS measures, these general adult respondents on average perceived a year of life with transfeminine vocal gender dysphoria as approximately three-quarters of a life-year of perfect health. Respondents also on average would have risked a 15%-20% chance of death on SG analysis and would have sacrificed 10 years of their remaining life on TTO measures to cure the condition. The QALY scores for the post-gender affirming treatments for vocal gender dysphoria (+0.09 VAS, p < 0.01) were significantly higher compared to the pretreatment state. There were no differences in the severity of these QALY scores by survey respondent's political affiliation or gender identity. Conclusions: To our knowledge, this study is the first to quantify how the general population perceives the health burden of vocal gender dysphoria experienced by transfeminine patients. Feminization treatments including voice therapy with feminization laryngoplasty appear to significantly increase health utility scores.
CORONARY ARTERY BYPASS GRAFTING IMPROVES 10 YEAR OUTCOMES IN HEART FAILURE AND PRESERVED EJECTION FRACTION - A NATIONWIDE STUDY
Authors: Salil Deo, Yogesh Reddy, Padmini Selvaganesan, Joseph Rubelowsky, Yakov Elgudin, Sri Krishna Madan Mohan, Richard Josephson, Brian Cmolik, Ahmet Kilic, Jayakumar Sahadevan, Varun Sundaram
Journal: Journal of the American College of Cardiology (2021)
PULMONARY HYPERTENSION AND POST HEART TRANSPLANTATION OUTCOMES: A CONTEMPORARY ANALYSIS
Authors: Osama Mahmoud, Eiran Gorodeski, Michael Zacharias, Marc P. Pelletier, Monique Robinson, Yakov Elgudin, Meisam Moghbelli, Chantal ElAmm, Yasir Abu-Omar
Journal: Journal of the American College of Cardiology (2021)
PROGRESSION OF CORONARY CALCIUM AND ALL-CAUSE MORTALITY IN PERSONS WITH END STAGE RENAL DISEASE
Authors: Audelia Arasheben, April Kinninger, Suraj Dahal, Suvasini Lakshmanan, Ahmed Ghanem, Vahid Rezvanizadeh, Khadije Ahmad, Kamyar Kalantar-Zadeh, Connie Rhee, Elani Streja, Amy You, Geoffrey Cho, Ronald Karlsberg, Matthew Budoff
Journal: Journal of the American College of Cardiology (2021)
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies
Authors: Richard R. Furman, John C. Byrd, Roger G. Owen, Susan M. O’Brien, Jennifer R. Brown, Peter Hillmen, Deborah M. Stephens, Nataliya Chernyukhin, Tamara Lezhava, Ahmed M. Hamdy, Raquel Izumi, Priti Patel, Marshall Baek, Beth Christian, Martin J. S. Dyer, Matthew J. Streetly, Clare Sun, Simon Rule, Michael Wang, Paolo Ghia, Wojciech Jurczak, John M. Pagel, Jeff P. Sharman
Journal: Leukemia (2021)
RARE CASE OF CONSTRICTIVE PERICARDITIS DUE TO METASTATIC PERICARDIAL MALIGNANCY WITHOUT RECURRENCE TO PRIMARY MALIGNANT SITE
Authors: Biren D. Patel, Abanoub Rushdy, Bhavik Patel, Muhammad Atif Masood Noori, Meherwan Joshi, Fayez Shamoon, Preet Mohan Randhawa
Journal: Journal of the American College of Cardiology (2021)
CONTEMPORARY PREVALENCE ESTIMATES OF UNDIAGNOSED AND DIAGNOSED ATRIAL FIBRILLATION IN THE UNITED STATES
Authors: Mintu Turakhia, Jennifer D. Guo, Allison Keshishian, Rachel Delinger, Xiaoxi Sun, Mauricio Ferri, Cristina Russ, Birol Emir, Matthew Cato, Huseyin Yuce, Patrick Hlavacek
Journal: Journal of the American College of Cardiology (2021)
THE IMPACT OF ANNUAL OPERATOR VOLUME ON THE OUTCOMES OF CHRONIC TOTAL OCCLUSION PERCUTANEOUS CORONARY INTERVENTION
Authors: Judit Karacsonyi, Ioannis Tsiafoutis, Khaldoon Alaswad, Jaikirshan Khatri, James Choi, Dimitrios Karmpaliotis, Ahmed ElGuindy, Abdul M. Sheikh, Wissam Jaber, Basem Elbarouni, Farouc Jaffer, Paul Poomipanit, Raj Chandwaney, Oleg Krestianinov, Barry Uretsky, Mitul Patel, Catalin Toma, Robert Yeh, Evangelia Vemmou, Ilias Nikolakopoulos, Iosif Xenogiannis, Bavana Rangan, Imre Ungi, Emmanouil Brilakis, Michalis Koutouzis
Journal: Journal of the American College of Cardiology (2021)
STRICT COMPLIANCE WITH ESC MEDICAL THERAPY GUIDELINES CORRELATES WITH IMPROVED 18-MONTH OUTCOMES AFTER MYOCARDIAL INFARCTION TREATED WITH PRIMARY ANGIOPLASTY
Authors: Jaroslaw D. Kasprzak, Edward Jankowski, Jan Z. Peruga, Michal Plewka, Radoslaw Krecki, Tomasz Wcislo, Marcin Fiutowski, Lukasz Jankowski, Bartosz Hudzik, Mariusz Gasior, Marek Gierlotka
Journal: Journal of the American College of Cardiology (2021)
Presentation and management of diverse cutaneous reactions after cyclin-dependent kinase 4/6 inhibitor use
Authors: Morgan Amigo, Kalyn Hoffman, Catherine Chung, Maryam Lustberg, Robert Wesolowski, Jeffrey VanDeusen, Daniel Stover, Gabriel Tinoco Suarez, Mathew Cherian, Benjamin Kaffenberger, Brittany Dulmage
Journal: Journal of the American Academy of Dermatology (2021)
Dried Blood Spot Testing for Detection of Congenital Cytomegalovirus—Reply
Authors: Mark R. Schleiss, Mark T. McCann, Sheila C. Dollard
Journal: JAMA Pediatrics (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Dilip Kumar Banerjee
Authors: Shrilla Banerjee
Journal: BMJ (2021)

Dilip Kumar Banerjee was an eminent doctor, academic, and university teacher who spent his entire 34-year career in the UK, working at St George’s Hospital in London. He was born in 1936 in Rajsahi, India (which subsequently became Bangladesh), and moved to Kolkata just before the partition of India. As a child, he lost his brother and mother to tuberculosis; mycobacteria then became his lifelong professional focus.

Dilip joined Calcutta National Medical College in 1953. Aside from studying medicine, he was active in the Students’ Union and in the Students’ Health Home (an organisation that provided healthcare and medication to those who could not afford them and is still active today). He graduated in 1958, working first in Kolkata, but moving in 1964 to the prestigious All India Institute …
Abstract 12920: Thyroid Disease as a Novel Risk Factor for Coronary Artery Calcification in Hemodialysis Patients
Authors: Connie Rhee, Matthew Budoff, Alejandra Novoa, Amy You, Tracy Nakata, Danh Nguyen, Kamyar Kalantar-Zadeh
Journal: Circulation (2018)

Background: Hypothyroidism is a highly prevalent yet underrecognized complication in hemodialysis (HD) patients. In the general population, hypothyroidism has been associated with coronary heart di...
SOCIOECONOMIC STATUS AND IN-HOSPITAL OUTCOMES AFTER CORONARY ARTERY REVASCULARIZATION
Authors: Alexis K. Okoh, Fady Soliman, Joshua Chao, Deng Xiaoyan, Kayla N. Laraia, Christoph Sossou, Mark Russo, Chunguang Chen, Leonard Lee
Journal: Journal of the American College of Cardiology (2021)
Severe asthma in the era of COVID-19: A narrative review
Authors: João Gaspar-Marques, Mafalda van Zeller, Pedro Carreiro-Martins, Cláudia Chaves Loureiro
Journal: Pulmonology (2021)

Severe asthma management during the coronavirus disease 2019 (COVID-19) pandemic is a challenge and will continue to be, at least in the next few months, as herd immunity is still a mirage. A lot has to be learned about how COVID-19 affects underlying diseases, and severe asthma is no exception. Narrative review of papers available until February 2021 in PubMed and Google Scholar, relating severe asthma and COVID-19. Four main research topics were reviewed: SARS-CoV-2 infection: immunology and respiratory pathology; interrelationship of severe asthma endotypes and COVID-19 disease mechanisms; severe asthma epidemiology and COVID-19; and biologics for severe asthma in the context of COVID-19. COVID-19 disease mechanisms start with upper respiratory cell infection, and afterwards several immunological facets are activated, contributing to disease severity, namely cell-mediated immunity and antibody production. Although infrequent in the COVID-19 course some patients develop a cytokine storm that causes organ damage and may lead to acute respiratory distress syndrome or multiorgan failure. Regarding severe asthma endotypes, type2-high might have a protective role both in infection risk and disease course. There is conflicting data regarding the epidemiological relationship between COVID-19 among severe asthma patients, with some studies reporting increased risk of infection and disease course, whereas others the other way round. Biologics for severe asthma do not seem to increase the risk of infection and severe COVID-19, although further evidence is needed. Globally, in the era of COVID-19, major respiratory societies recommend continuing the biologic treatment, preferably in a self-home administration program.
TROPONIN CORRELATES WITH INFLAMMATORY MARKERS IN COVID-19
Authors: Brent Klinkhammer, Ronaldo Go, Steven Hollenberg, David Landers, Zoltan Turi, Taya Glotzer, Sameer Jamal, Lucy Safi, Noha Gayed, Matthew Fata, Jana Tancredi, Elli Gourna-Paleoudis, Michael Marafelias, Themba Nyirenda, Spencer Haber, Thomas Jaten, Neel Shah, Roshan Shah, Joseph Parrillo
Journal: Journal of the American College of Cardiology (2021)
A generalization of t-SNE and UMAP to single-cell multimodal omics
Authors: Van Hoan Do, Stefan Canzar
Journal: Genome biology (2021)

Abstract Emerging single-cell technologies profile multiple types of molecules within individual cells. A fundamental step in the analysis of the produced high-dimensional data is their visualization using dimensionality reduction techniques such as t-SNE and UMAP. We introduce j-SNE and j-UMAP as their natural generalizations to the joint visualization of multimodal omics data. Our approach automatically learns the relative contribution of each modality to a concise representation of cellular identity that promotes discriminative features but suppresses noise. On eight datasets, j-SNE and j-UMAP produce unified embeddings that better agree with known cell types and that harmonize RNA and protein velocity landscapes.
Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS)
Authors: Luca S. Belli, Christophe Duvoux, Thierry Artzner, William Bernal, Sara Conti, Paolo A. Cortesi, Sophie-Caroline Sacleux, George-Philippe Pageaux, Sylvie Radenne, Jonel Trebicka, Javier Fernandez, Giovanni Perricone, Salvatore Piano, Silvio Nadalin, Maria C. Morelli, Silvia Martini, Wojciech G. Polak, Krzysztof Zieniewicz, Christian Toso, Marina Berenguer, Claudia Iegri, Federica Invernizzi, Riccardo Volpes, Vincent Karam, René Adam, François Faitot, Liane Rabinovich, Faouzi Saliba, Lucy Meunier, Mickael Lesurtel, Frank E. Uschner, Costantino Fondevila, Baptiste Michard, Audrey Coilly, Magdalena Meszaros, Domitille Poinsot, Andreas Schnitzbauer, Luciano G. De Carlis, Roberto Fumagalli, Paolo Angeli, Vincente Arroyo, Rajiv Jalan, Luca S. Belli, Giovanni Perricone, Raffaella Viganò, Chiara Mazzarelli, Luciano G. De Carlis, Andrea Lauterio, Alessandro Giacomoni, Federica Invernizzi, Francesca Donato, Pietro Lampertico, Claudia Iegri, Luisa Pasulo, Stefano Fagiuoli, Michele Colledan, Maria Cristina Morelli, Giovanni Vitale, Damiano Patrono, Renato Romagnoli, Silvia Martini, Antonio Ottobrelli, Riccardo Volpes, Ioannis Petridis, Salvatore Piano, Paolo Angeli, Umberto Cillo, Giacomo Germani, Patrizia Burra, Thierry Artzner, Philippe Bachellier, Pietro Addeo, Camille Besch, Francoise Faitot, Baptiste Michard, Sophie Caroline Sacleux, Audrey Coilly, Saliba Faouzi, Rene Adam, Didier Samuel, Christophe Duvoux, Sylvie Radenne, Mickael Lesurtel, Domitille Poinsot, Celine Guichon, George-Philippe Pageaux, Stéfanie Faure, Magdalena Meszaros, Lucy Meunier, Josè Ursic-Bedoya, Costantino Fondevila, Jorde Colmenero, David Toapanta, María Hernández-Tejero, Marina Berenguer, Carmen Vinaixa, Wojciech G. Polak, Caroline den Hoed, Jubi E. de Haan, Silvio Nadalin, Andrea Della Penna, Frank Erhard Uschner, Martin Welker, Andreas Schnitzbauer, Stefan Zeuzem, Wolf Bechstein, Jonel Trebicka, Christian Toso, Nicolas Goossens, Joanna Raszeja-Wyszomirska, Krzysztof Zieniewicz, William Bernal, Liane Rabinovich, Dev Katarey, Banwari Agarwal, Rajiv Jalan
Journal: Journal of Hepatology (2021)
Covid-19: Two doses of Pfizer vaccine are “highly effective” against infection, hospital admission, and death, study finds
Authors: Gareth Iacobucci
Journal: BMJ (2021)

Covid-19: Two doses of Pfizer vaccine are "highly effective" against infection, hospital admission, and death, study finds Gareth IacobucciTwo doses of the Pfizer-BioNTech covid-19 vaccine provide more than 95% protection against infection, hospital admission, and death, including among older people, a peer reviewed study from Israel has found.A single dose of the Pfizer vaccine was associated with 58% protection against infection, 76% against hospital admission, and 77% against death, the study published in the Lancet reported. 1The findings also indicate that vaccine coverage was the "primary driver" in reductions in covid-19 infections in Israel, not lockdown, the researchers said.Lead author Sharon Alroy-Preis of the Israel Ministry of Health, said, "These insights are hugely important because, while there are still some considerable challenges to overcome, they offer real hope that covid-19 vaccination will eventually enable us to control the pandemic."Israel, which currently has the highest proportion of its population vaccinated against covid-19, is the first country to report national data on Pfizer's vaccine. 1
ASSOCIATION BETWEEN VENTRICULAR TACHYCARDIA AND MORTALITY IN PATIENTS WITH CARDIAC SARCOIDOSIS
Authors: Jose Aguilera, Maria Vega Brizneda, Erika Hutt, Ziad Taimeh, Daniel Culver, Thomas Callahan, Oussama Wazni, Wael Jaber, Manuel Ribeiro, Scott Flamm, Christine Jellis
Journal: Journal of the American College of Cardiology (2021)
THE IMPACT OF COVID-19 ON PATIENTS PRESENTING WITH ACUTE CORONARY SYNDROME
Authors: Nathan Zaher, Rashid Alhusain, Adnan Haboni, Tarec Misho Ubeh, Abdul-Rahman Suleiman, Mohamad Soudan, Yasar Sattar, Joseph Sebastian, Mohamed Zghouzi, Bachar Ahmad, Antoinette Stewart, Caleb Sokolowski, Abubakr Ziaullah, Aiden Abidov, M. Chadi Alraies
Journal: Journal of the American College of Cardiology (2021)
TEMPORAL TRENDS IN NON-CARDIOVASCULAR COMORBIDITIES AMONG PATIENTS HOSPITALIZED WITH ACUTE VS CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION: THE ARIC STUDY
Authors: Zainali Chunawala, Robert Mentz, Marat Fudim, Melissa Caughey, Sameer Arora, Arman Qamar, Muthiah Vaduganathan, Ambarish Pandey
Journal: Journal of the American College of Cardiology (2021)
Influence of Obesity on Factor IX Expression after Gene Therapy in a Mouse Model of Hemophilia B
Authors: Sogué Coulibaly, Markus Weiller, Alexander Bauer, Johannes Lengler, Stefan Romeder-Finger, Alexandra Kopić, Karima Benamara, Paul Monahan, Hanspeter Rottensteiner, Friedrich Scheiflinger, Marietta Turecek, Werner Hoellriegl
Journal: Blood (2017)
Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials
Authors: Ghulam Rehman Mohyuddin, Kelly Koehn, Al-Ola Abdallah, Aaron M. Goodman, Vinay Prasad
Journal: JAMA Network Open (2021)

<h3>Importance</h3> A thorough understanding of the optimal role and sequence of agents for treatment of multiple myeloma (MM) requires knowledge of the use and rate of postprotocol therapies in randomized clinical trials (RCTs). <h3>Objectives</h3> To examine the proportion of MM RCTs that reported postprotocol therapies and, among those, the percentage of patients who received no further therapy and how treatments differed between the control and intervention arms. <h3>Evidence Review</h3> The reporting of postprotocol therapies was systematically assessed in published MM RCTs using 3 databases (PubMed, Embase, and Cochrane Registry of Controlled Trials) for MM RCTs from January 1, 2005, to December 30, 2019. All MM RCTs were included, and all other studies, such as editorials, nonrandomized studies, and review articles, were excluded. <h3>Findings</h3> A total of 103 RCTs were identified (47 251 patients); of these, 45 (43.7%) reported subsequent treatments in that publication or in any subsequent publication. Trials funded by pharmaceutical companies (26 of 47 [55.3%]) were more likely to report subsequent treatments than cooperative group studies (19 of 56 [33.9%]) (χ<sup>2</sup><sub>1,103</sub> = 4.8;<i>P</i> = .03). Differences were found in the treatments received between the intervention and control arms of RCTs. When data were reported, 5150 of 9351 patients (54.9%) in RCTs of newly diagnosed MM and 2197 of 4501 patients (48.8%) in RCTs of relapsed/refractory MM received any subsequent therapy. <h3>Conclusions and Relevance</h3> Postprotocol therapies in MM RCTs are often not reported and, when they are, many patients receive no further therapy. Reporting guidelines for postprotocol therapies are needed.
META-ANALYSIS OF DIRECT ORAL ANTICOAGULANT VERSUS VITAMIN K ANTAGONIST IN PATIENTS WITH ATRIAL FIBRILLATION AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Waiel Abusnina, Ahmad Al-Abdouh, Gauravpal S. Gill, Anas Bizanti, Abdelrazeg Houssein, Aiman Smer
Journal: Journal of the American College of Cardiology (2021)
ONE VERSUS TWO CRYOBALLOON ABLATIONS PER PULMONARY VEIN FOR PAROXYSMAL ATRIAL FIBRILLATION: THE ONE FREEZE TRIAL
Authors: Byron Kwock Lee, Peter Guerra, Robert Rho, Marc Dubuc, Katia Dyrda, Christopher Fellows, Randall Lee, Trisha Hue, Shabir Sarwary, Keith Uyemura, Feng Lin, Edward Gerstenfeld
Journal: Journal of the American College of Cardiology (2021)
REDUCTION IN QRS 3D VOLTAGE TIME INTERVAL (3D QRS AREA) IS ASSOCIATED WITH IMPROVEMENT IN LEFT VENTRICLUAR EJECTION FRACTION AMONG HEART FAILURE PATIENTS ON SACUBITRIL-VALSARTAN
Authors: Nikhil Parimi, Uzair Mahmood, Anas Abudan, Farhad Sami, Christopher Harvey, Colton Schwarz, Michael Pierpoline, Andrew Sauer, Bhanu Gupta, Madhu Reddy, Seth Sheldon, Amit Noheria
Journal: Journal of the American College of Cardiology (2021)
Preclinical Models of Cancer Therapy–Associated Cardiovascular Toxicity: A Scientific Statement From the American Heart Association
Authors: Aarti Asnani, Javid J. Moslehi, Bishow B. Adhikari, Alan H. Baik, Andreas M. Beyer, Rudolf A. de Boer, Alessandra Ghigo, Isabella M. Grumbach, Salvia Jain, Han Zhu
Journal: Circulation Research (2021)

Although cardiovascular toxicity from traditional chemotherapies has been well recognized for decades, the recent explosion of effective novel targeted cancer therapies with cardiovascular sequelae has driven the emergence of cardio-oncology as a new clinical and research field. Cardiovascular toxicity associated with cancer therapy can manifest as a broad range of potentially life-threatening complications, including heart failure, arrhythmia, myocarditis, and vascular events. Beyond toxicology, the intersection of cancer and heart disease has blossomed to include discovery of genetic and environmental risk factors that predispose to both. There is a pressing need to understand the underlying molecular mechanisms of cardiovascular toxicity to improve outcomes in patients with cancer. Preclinical cardiovascular models, ranging from cellular assays to large animals, serve as the foundation for mechanistic studies, with the ultimate goal of identifying biologically sound biomarkers and cardioprotective therapies that allow the optimal use of cancer treatments while minimizing toxicities. Given that novel cancer therapies target specific pathways integral to normal cardiovascular homeostasis, a better mechanistic understanding of toxicity may provide insights into fundamental pathways that lead to cardiovascular disease when dysregulated. The goal of this scientific statement is to summarize the strengths and weaknesses of preclinical models of cancer therapy-associated cardiovascular toxicity, to highlight overlapping mechanisms driving cancer and cardiovascular disease, and to discuss opportunities to leverage cardio-oncology models to address important mechanistic questions relevant to all patients with cardiovascular disease, including those with and without cancer.
MEASURING THE BOUNDARY LAYERS IN PATIENTS WITH ACUTE CORONARY SYNDROME BY DYNAMIC ANGIOGRAPHY AND MACHINE LEARNING PROGRAM
Authors: Thach N. Nguyen, Loc Vu, Gianluca Rigatelli, Ernest Talarico, Thinh Cao, Dzung Ho, Hien Duong, Dien Pham, Duy Chung, Luan Ngo, Tra Ngo, Duc Truong
Journal: Journal of the American College of Cardiology (2021)